In-PharmaTechnologist steps inside Siemen's Digital Experience Centre to learn about the digital services that aim to transform the manufacturing of pharmaceuticals.
Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.
It’s a lot more complicated than a simple technology – says Iqvia global head of virtual trials, who shares four lessons learned during a discussion at the company’s headquarters in Research Triangle Park.
Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
There is an increased need for transparency to improve the conduct of pediatric clinical trials and enhance the site investigator experience, says Syneos executive.
The drug development “finish line” is not regulatory approval, says Syenos Health chief scientific officer Judith Ng-Cashin, MD, who discusses bringing the payer and patient voice into the process.
PPD Laboratories SVP says its been a substantial undertaking – for every company in the CRO industry – to meet the demand for biopharmaceuticals as the industry's pipeline continues to expand.
Advanced imaging in drug discovery aims to improve the success rate of drug development as the industry continues to tackle devastating diseases such as Alzheimer’s – but no research lab can do it alone, says Charles River managing director.
When translational medicine researchers recognise the need for pharma industry cash but are wary of handing over drug development to for-profit organisations, how can public-private collaborations bridge the culture gap?
The holidays are fast upon us, so let’s put ‘business’ to one side and get into the festive mood. To keep in the spirit of things, we’ve got a ‘gift’ for you – enjoy. Happy Holidays!
Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
